Join the Nirmatrelvir / ritonavir group to help and get support from people like you.
Nirmatrelvir / ritonavir News
Postexposure Prophylaxis With Nirmatrelvir-Ritonavir Does Not Cut COVID-19 Infection
THURSDAY, July 18, 2024 – Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 – A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2 infection (PASC)...
Extended Course of Paxlovid Adds No Benefit for Those With Long COVID
FRIDAY, June 7, 2024 – An extended course of the antiviral drug Paxlovid won’t ease a person’s Long COVID symptoms, a new study finds. People who took Paxlovid for 15 days – three times as long as i...
Nirmatrelvir-Ritonavir Does Not Speed Up Alleviation of COVID-19 Symptoms
FRIDAY, April 5, 2024 – For patients with confirmed COVID-19, nirmatrelvir-ritonavir is not associated with a shorter time to sustained alleviation of symptoms than placebo, according to a study...
COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
WEDNESDAY, March 20, 2024 – For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or...
Nirmatrelvir During Acute SARS-CoV-2 Does Not Reduce Risk for Long COVID
FRIDAY, Jan. 5, 2024 – Treatment with nirmatrelvir during acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not associated with a reduced risk for subsequent...
SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
FRIDAY, Dec. 22, 2023 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those...
Virologic Rebound Occurs in ~20 Percent Receiving Nirmatrelvir-Ritonavir
TUESDAY, Nov. 14, 2023 – For patients receiving nirmatrelvir-ritonavir (N-R) for acute COVID-19, virologic rebound (VR) occurs in about one in five, according to a study published online Nov. 14 in...
COVID Meds Like Paxlovid Will Soon Have Big Price Tags
MONDAY, Oct. 30, 2023 – Americans have been getting COVID treatments such as Paxlovid for free, but that’s about to end. The medications will enter the private market this week, the Associated Press ...
Nirmatrelvir/Ritonavir Cuts COVID-19 Complications in Highest-Risk Patients
WEDNESDAY, Oct. 4, 2023 – For individuals with the highest risk for complications from COVID-19 infection, nirmatrelvir and ritonavir is associated with a reduced risk for COVID-19 hospitalization...
Nirmatrelvir, Molnupiravir Use Lowers Risks for Omicron-Infected
MONDAY, Sept. 25, 2023 – For patients infected with omicron at high risk for progression to severe disease, treatment with nirmatrelvir or molnupiravir is associated with reductions in mortality and...
Practice Points Developed for Treatment of Outpatient COVID-19
WEDNESDAY, Sept. 20, 2023 – In an updated clinical guideline issued by the American College of Physicians and published online Sept. 19 in the Annals of Internal Medicine, living, rapid practice...
FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk of Progression to Severe COVID-19
NEW YORK--(BUSINESS WIRE) May 25, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) for t...
Ask a question
To post your own question to this support group, sign in or create an account.